380 related articles for article (PubMed ID: 28922433)
21. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
22. Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized pilot studies.
Dore MP; Bibbò S; Loria M; Salis R; Manca A; Pes GM; Graham DY
Helicobacter; 2019 Dec; 24(6):e12659. PubMed ID: 31502382
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Zheng Q; Pan Y; Zhang L; Xiao SD
Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
[TBL] [Abstract][Full Text] [Related]
24. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Sep; 21(35):10234-41. PubMed ID: 26401089
[TBL] [Abstract][Full Text] [Related]
26. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
[TBL] [Abstract][Full Text] [Related]
27. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK
J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161
[TBL] [Abstract][Full Text] [Related]
28. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Dore MP; Farina V; Cuccu M; Mameli L; Massarelli G; Graham DY
Helicobacter; 2011 Aug; 16(4):295-300. PubMed ID: 21762269
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study.
O'Morain C; Borody T; Farley A; De Boer WA; Dallaire C; Schuman R; Piotrowski J; Fallone CA; Tytgat G; Mégraud F; Spénard J;
Aliment Pharmacol Ther; 2003 Feb; 17(3):415-20. PubMed ID: 12562455
[TBL] [Abstract][Full Text] [Related]
30. A novel hybrid first-line therapy for H. pylori eradication: results of a pilot study.
De Francesco V
J Gastrointestin Liver Dis; 2019 Mar; 28(1):129-130. PubMed ID: 30851183
[No Abstract] [Full Text] [Related]
31. Eradication of Helicobacter pylori infection with a new bismuth-based quadruple therapy in clinical practice.
Pérez-Arellano E; Rodriguez-Garcia MI; Galera Rodenas AB; de la Morena-Madrigal E
Gastroenterol Hepatol; 2018 Mar; 41(3):145-152. PubMed ID: 29054320
[TBL] [Abstract][Full Text] [Related]
32. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.
Cao Z; Chen Q; Zhang W; Liang X; Liao J; Liu W; Xiao S; Lu H
Scand J Gastroenterol; 2015; 50(10):1185-90. PubMed ID: 25881966
[TBL] [Abstract][Full Text] [Related]
33. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
34. Pylera for the eradication of Helicobacter pylori infection.
Saleem A; Qasim A; O'Connor HJ; O'Morain CA
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):793-9. PubMed ID: 19735221
[TBL] [Abstract][Full Text] [Related]
35. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea.
Yoon K; Kim N; Lee JW; Yoon H; Shin CM; Park YS; Lee DH
Helicobacter; 2020 Jun; 25(3):e12685. PubMed ID: 32141173
[TBL] [Abstract][Full Text] [Related]
36. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori.
Delchier JC; Malfertheiner P; Thieroff-Ekerdt R
Aliment Pharmacol Ther; 2014 Jul; 40(2):171-7. PubMed ID: 24863854
[TBL] [Abstract][Full Text] [Related]
37. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.
Liou JM; Chen PY; Luo JC; Lee JY; Chen CC; Fang YJ; Yang TH; Chang CY; Bair MJ; Chen MJ; Hsu YC; Hsu WF; Chang CC; Lin JT; Shun CT; El-Omar EM; Wu MS;
Gastroenterology; 2018 Oct; 155(4):1109-1119. PubMed ID: 29964036
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice.
Shaikh T; Fallone CA
Can J Gastroenterol Hepatol; 2016; 2016():7321574. PubMed ID: 27446864
[TBL] [Abstract][Full Text] [Related]
39. Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days.
Knigge K; Kelly C; Peterson WL; Fennerty MB
Aliment Pharmacol Ther; 1999 Mar; 13(3):323-6. PubMed ID: 10102965
[TBL] [Abstract][Full Text] [Related]
40. Compliance, adverse effects and effectiveness of first line bismuth-containing quadruple treatment (Pylera®) to eradicate Helicobacter pylori infection in 200 patients.
Castro Fernández M; Romero García T; Keco Huerga A; Pabón Jaén M; Lamas Rojas E; Llorca Fernández R; Grande Santamaría L; Rojas Feria M
Rev Esp Enferm Dig; 2019 Jun; 111(6):467-470. PubMed ID: 31117799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
